ID   SOX2_HUMAN              Reviewed;         317 AA.
AC   P48431; Q14537;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   18-JUN-2025, entry version 214.
DE   RecName: Full=Transcription factor SOX-2;
GN   Name=SOX2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=7849401; DOI=10.1007/bf00411460;
RA   Stevanovic M., Zuffardi O., Collignon J., Lovell-Badge R., Goodfellow P.;
RT   "The cDNA sequence and chromosomal location of the human SOX2 gene.";
RL   Mamm. Genome 5:640-642(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RA   Sadler L.A., Badzioch M.D., Wagner M., Graves K.A., Swaroop A.,
RA   Yang-Feng T.L., Zheng K., Daiger S.P.;
RL   Submitted (DEC-1992) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INVOLVEMENT IN MCOPS3.
RX   PubMed=12612584; DOI=10.1038/ng1120;
RA   Fantes J., Ragge N.K., Lynch S.-A., McGill N.I., Collin J.R.O.,
RA   Howard-Peebles P.N., Hayward C., Vivian A.J., Williamson K.,
RA   van Heyningen V., FitzPatrick D.R.;
RT   "Mutations in SOX2 cause anophthalmia.";
RL   Nat. Genet. 33:461-463(2003).
RN   [5]
RP   BIOTECHNOLOGY, AND FUNCTION.
RX   PubMed=18035408; DOI=10.1016/j.cell.2007.11.019;
RA   Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K.,
RA   Yamanaka S.;
RT   "Induction of pluripotent stem cells from adult human fibroblasts by
RT   defined factors.";
RL   Cell 131:861-872(2007).
RN   [6]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF 42-LYS-ARG-43; 56-ARG--LYS-58 AND
RP   113-ARG--LYS-115.
RX   PubMed=19349578; DOI=10.1083/jcb.200810106;
RA   Gontan C., Guettler T., Engelen E., Demmers J., Fornerod M., Grosveld F.G.,
RA   Tibboel D., Goerlich D., Poot R.A., Rottier R.J.;
RT   "Exportin 4 mediates a novel nuclear import pathway for Sox family
RT   transcription factors.";
RL   J. Cell Biol. 185:27-34(2009).
RN   [7]
RP   INTERACTION WITH GLIS1.
RX   PubMed=21654807; DOI=10.1038/nature10106;
RA   Maekawa M., Yamaguchi K., Nakamura T., Shibukawa R., Kodanaka I.,
RA   Ichisaka T., Kawamura Y., Mochizuki H., Goshima N., Yamanaka S.;
RT   "Direct reprogramming of somatic cells is promoted by maternal
RT   transcription factor Glis1.";
RL   Nature 474:225-229(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-251, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [9]
RP   VARIANTS MCOPS3 ARG-51; PRO-74 AND SER-79.
RX   PubMed=24033328; DOI=10.1111/cge.12275;
RA   Chassaing N., Causse A., Vigouroux A., Delahaye A., Alessandri J.L.,
RA   Boespflug-Tanguy O., Boute-Benejean O., Dollfus H., Duban-Bedu B.,
RA   Gilbert-Dussardier B., Giuliano F., Gonzales M., Holder-Espinasse M.,
RA   Isidor B., Jacquemont M.L., Lacombe D., Martin-Coignard D.,
RA   Mathieu-Dramard M., Odent S., Picone O., Pinson L., Quelin C., Sigaudy S.,
RA   Toutain A., Thauvin-Robinet C., Kaplan J., Calvas P.;
RT   "Molecular findings and clinical data in a cohort of 150 patients with
RT   anophthalmia/microphthalmia.";
RL   Clin. Genet. 86:326-334(2014).
RN   [10]
RP   METHYLATION AT LYS-42 AND LYS-117, INTERACTION WITH PHF20L1, AND
RP   MUTAGENESIS OF LYS-42 AND LYS-117.
RX   PubMed=29358331; DOI=10.1074/jbc.ra117.000342;
RA   Zhang C., Hoang N., Leng F., Saxena L., Lee L., Alejo S., Qi D., Khal A.,
RA   Sun H., Lu F., Zhang H.;
RT   "LSD1 demethylase and the methyl-binding protein PHF20L1 prevent SET7
RT   methyltransferase-dependent proteolysis of the stem-cell protein SOX2.";
RL   J. Biol. Chem. 293:3663-3674(2018).
RN   [11]
RP   INTERACTION WITH TRIM26, AND UBIQUITINATION BY WWP2.
RX   PubMed=34732716; DOI=10.1038/s41467-021-26653-6;
RA   Mahlokozera T., Patel B., Chen H., Desouza P., Qu X., Mao D.D., Hafez D.,
RA   Yang W., Taiwo R., Paturu M., Salehi A., Gujar A.D., Dunn G.P.,
RA   Mosammaparast N., Petti A.A., Yano H., Kim A.H.;
RT   "Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in
RT   glioblastoma.";
RL   Nat. Commun. 12:6321-6321(2021).
RN   [12]
RP   INTERACTION WITH L3MBTL3 AND DCAF5, AND MUTAGENESIS OF LYS-42.
RX   PubMed=30442713; DOI=10.1074/jbc.ra118.005336;
RA   Zhang C., Leng F., Saxena L., Hoang N., Yu J., Alejo S., Lee L., Qi D.,
RA   Lu F., Sun H., Zhang H.;
RT   "Proteolysis of methylated SOX2 protein is regulated by L3MBTL3 and CRL4-
RT   DCAF5 ubiquitin ligase.";
RL   J. Biol. Chem. 294:476-489(2019).
CC   -!- FUNCTION: Transcription factor that forms a trimeric complex with OCT4
CC       on DNA and controls the expression of a number of genes involved in
CC       embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By
CC       similarity). Binds to the proximal enhancer region of NANOG (By
CC       similarity). Critical for early embryogenesis and for embryonic stem
CC       cell pluripotency (PubMed:18035408). Downstream SRRT target that
CC       mediates the promotion of neural stem cell self-renewal (By
CC       similarity). Keeps neural cells undifferentiated by counteracting the
CC       activity of proneural proteins and suppresses neuronal differentiation
CC       (By similarity). May function as a switch in neuronal development (By
CC       similarity). {ECO:0000250|UniProtKB:P48430,
CC       ECO:0000250|UniProtKB:P48432, ECO:0000269|PubMed:18035408}.
CC   -!- SUBUNIT: Interacts with ZSCAN10 (By similarity). Interacts with SOX3
CC       and FGFR1 (By similarity). Interacts with GLIS1 (PubMed:21654807).
CC       Interacts with POU5F1; binds synergistically with POU5F1 to DNA (By
CC       similarity). Interacts with DDX56 (By similarity). Interacts with
CC       L3MBTL3 and DCAF5; the interaction requires methylation at Lys-42 and
CC       is necessary to target SOX2 for ubiquitination by the CRL4-DCAF5 E3
CC       ubiquitin ligase complex (PubMed:30442713). Interacts with RCOR1/CoREST
CC       (By similarity) (PubMed:30442713). Interacts with PHF20L1; the
CC       interaction requires methylation at Lys-42 and Lys-117 and protects
CC       SOX2 from degradation (PubMed:29358331). Interacts with TRIM26; this
CC       interaction prevents ubiquitination by WWP2 (PubMed:34732716).
CC       {ECO:0000250|UniProtKB:P48432, ECO:0000269|PubMed:21654807,
CC       ECO:0000269|PubMed:29358331, ECO:0000269|PubMed:30442713,
CC       ECO:0000269|PubMed:34732716}.
CC   -!- INTERACTION:
CC       P48431; O95983: MBD3; NbExp=3; IntAct=EBI-6124081, EBI-1783068;
CC       P48431; Q01860: POU5F1; NbExp=2; IntAct=EBI-6124081, EBI-475687;
CC       P48431; P41743: PRKCI; NbExp=2; IntAct=EBI-6124081, EBI-286199;
CC       P48431; P63165: SUMO1; NbExp=4; IntAct=EBI-6124081, EBI-80140;
CC       P48431; Q93009: USP7; NbExp=3; IntAct=EBI-6124081, EBI-302474;
CC       P48431; Q99986: VRK1; NbExp=14; IntAct=EBI-6124081, EBI-1769146;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000250|UniProtKB:Q05066}.
CC       Cytoplasm {ECO:0000250|UniProtKB:Q05738}. Nucleus
CC       {ECO:0000250|UniProtKB:Q05738}. Note=Acetylation contributes to its
CC       nuclear localization and deacetylation by HDAC3 induces a cytoplasmic
CC       delocalization (By similarity). Colocalizes in the nucleus with ZNF208
CC       isoform KRAB-O and tyrosine hydroxylase (TH) (By similarity).
CC       Colocalizes with SOX6 in speckles. Colocalizes with CAML in the nucleus
CC       (By similarity). Nuclear import is facilitated by XPO4, a protein that
CC       usually acts as a nuclear export signal receptor (By similarity).
CC       {ECO:0000250|UniProtKB:Q05066, ECO:0000250|UniProtKB:Q05738}.
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000250|UniProtKB:P41225}.
CC   -!- PTM: Sumoylation inhibits binding on DNA and negatively regulates the
CC       FGF4 transactivation. {ECO:0000250}.
CC   -!- PTM: Methylation at Lys-42 and Lys-117 is necessary for the regulation
CC       of SOX2 proteasomal degradation. {ECO:0000269|PubMed:29358331,
CC       ECO:0000269|PubMed:30442713}.
CC   -!- PTM: Ubiquitinated by WWP2, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:34732716}.
CC   -!- DISEASE: Microphthalmia, syndromic, 3 (MCOPS3) [MIM:206900]: A disease
CC       characterized by the rare association of malformations including
CC       uni- or bilateral anophthalmia or microphthalmia, and esophageal
CC       atresia with trachoesophageal fistula. Microphthalmia is a disorder of
CC       eye formation, ranging from small size of a single eye to complete
CC       bilateral absence of ocular tissues (anophthalmia). In many cases,
CC       microphthalmia/anophthalmia occurs in association with syndromes that
CC       include non-ocular abnormalities. {ECO:0000269|PubMed:12612584,
CC       ECO:0000269|PubMed:24033328}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four
CC       Yamanaka factors. When combined, these factors are sufficient to
CC       reprogram differentiated cells to an embryonic-like state designated
CC       iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology
CC       and growth properties of ES cells and express ES cell marker genes.
CC       {ECO:0000269|PubMed:18035408}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35997.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA83435.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Sox2 entry;
CC       URL="https://en.wikipedia.org/wiki/Sox2";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44064/SOX2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z31560; CAA83435.1; ALT_INIT; mRNA.
DR   EMBL; L07335; AAA35997.1; ALT_INIT; mRNA.
DR   EMBL; BC013923; AAH13923.1; -; mRNA.
DR   CCDS; CCDS3239.1; -.
DR   RefSeq; NP_003097.1; NM_003106.4.
DR   PDB; 1O4X; NMR; -; B=39-121.
DR   PDB; 2LE4; NMR; -; A=39-118.
DR   PDB; 6T7B; EM; 5.10 A; K=36-121.
DR   PDB; 6T90; EM; 3.05 A; L=37-118.
DR   PDB; 6WX7; X-ray; 2.70 A; B=39-127.
DR   PDB; 6WX8; X-ray; 2.30 A; B/D=39-127.
DR   PDB; 6WX9; X-ray; 2.80 A; B=39-127.
DR   PDB; 6YOV; EM; 3.42 A; L=37-118.
DR   PDBsum; 1O4X; -.
DR   PDBsum; 2LE4; -.
DR   PDBsum; 6T7B; -.
DR   PDBsum; 6T90; -.
DR   PDBsum; 6WX7; -.
DR   PDBsum; 6WX8; -.
DR   PDBsum; 6WX9; -.
DR   PDBsum; 6YOV; -.
DR   AlphaFoldDB; P48431; -.
DR   BMRB; P48431; -.
DR   EMDB; EMD-10392; -.
DR   EMDB; EMD-10406; -.
DR   EMDB; EMD-10864; -.
DR   SMR; P48431; -.
DR   BioGRID; 112540; 1364.
DR   CORUM; P48431; -.
DR   DIP; DIP-59913N; -.
DR   FunCoup; P48431; 1519.
DR   IntAct; P48431; 493.
DR   MINT; P48431; -.
DR   STRING; 9606.ENSP00000323588; -.
DR   GlyCosmos; P48431; 1 site, 1 glycan.
DR   GlyGen; P48431; 9 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (7 sites).
DR   iPTMnet; P48431; -.
DR   PhosphoSitePlus; P48431; -.
DR   BioMuta; SOX2; -.
DR   DMDM; 1351091; -.
DR   jPOST; P48431; -.
DR   MassIVE; P48431; -.
DR   PaxDb; 9606-ENSP00000323588; -.
DR   PeptideAtlas; P48431; -.
DR   ProteomicsDB; 55888; -.
DR   Pumba; P48431; -.
DR   Antibodypedia; 3488; 1822 antibodies from 54 providers.
DR   DNASU; 6657; -.
DR   Ensembl; ENST00000325404.3; ENSP00000323588.1; ENSG00000181449.4.
DR   GeneID; 6657; -.
DR   KEGG; hsa:6657; -.
DR   MANE-Select; ENST00000325404.3; ENSP00000323588.1; NM_003106.4; NP_003097.1.
DR   UCSC; uc003fkx.4; human.
DR   AGR; HGNC:11195; -.
DR   CTD; 6657; -.
DR   DisGeNET; 6657; -.
DR   GeneCards; SOX2; -.
DR   GeneReviews; SOX2; -.
DR   HGNC; HGNC:11195; SOX2.
DR   HPA; ENSG00000181449; Tissue enhanced (brain, esophagus).
DR   MalaCards; SOX2; -.
DR   MIM; 184429; gene.
DR   MIM; 206900; phenotype.
DR   OpenTargets; ENSG00000181449; -.
DR   Orphanet; 77298; Anophthalmia/microphthalmia-esophageal atresia syndrome.
DR   Orphanet; 98938; Colobomatous microphthalmia.
DR   Orphanet; 35612; Nanophthalmos.
DR   Orphanet; 3157; Septo-optic dysplasia spectrum.
DR   VEuPathDB; HostDB:ENSG00000181449; -.
DR   eggNOG; KOG0527; Eukaryota.
DR   GeneTree; ENSGT00940000160614; -.
DR   HOGENOM; CLU_021123_0_0_1; -.
DR   InParanoid; P48431; -.
DR   OMA; MYNMMES; -.
DR   OrthoDB; 6247875at2759; -.
DR   PAN-GO; P48431; 9 GO annotations based on evolutionary models.
DR   PhylomeDB; P48431; -.
DR   PathwayCommons; P48431; -.
DR   Reactome; R-HSA-2892245; POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation.
DR   Reactome; R-HSA-2892247; POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2.
DR   Reactome; R-HSA-9754189; Germ layer formation at gastrulation.
DR   Reactome; R-HSA-9823739; Formation of the anterior neural plate.
DR   Reactome; R-HSA-9832991; Formation of the posterior neural plate.
DR   Reactome; R-HSA-9834899; Specification of the neural plate border.
DR   Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity.
DR   Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition.
DR   SignaLink; P48431; -.
DR   SIGNOR; P48431; -.
DR   BioGRID-ORCS; 6657; 60 hits in 1179 CRISPR screens.
DR   CD-CODE; 50D32664; Synthetic Condensate 000192.
DR   CD-CODE; CF22E771; Synthetic Condensate 000181.
DR   EvolutionaryTrace; P48431; -.
DR   GeneWiki; SOX2; -.
DR   GenomeRNAi; 6657; -.
DR   Pharos; P48431; Tbio.
DR   PRO; PR:P48431; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P48431; protein.
DR   Bgee; ENSG00000181449; Expressed in ventricular zone and 152 other cell types or tissues.
DR   ExpressionAtlas; P48431; baseline and differential.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; TAS:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0035198; F:miRNA binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0021984; P:adenohypophysis development; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0006325; P:chromatin organization; NAS:UniProtKB.
DR   GO; GO:0001714; P:endodermal cell fate specification; IDA:MGI.
DR   GO; GO:0001654; P:eye development; IEP:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEP:UniProtKB.
DR   GO; GO:0021781; P:glial cell fate commitment; NAS:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; IEP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; ISS:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0021983; P:pituitary gland development; IEP:UniProtKB.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:HGNC-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1904520; P:regulation of myofibroblast cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0070848; P:response to growth factor; IDA:UniProtKB.
DR   GO; GO:0090649; P:response to oxygen-glucose deprivation; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEP:UniProtKB.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IDA:UniProtKB.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   CDD; cd01388; HMG-box_SoxB; 1.
DR   FunFam; 1.10.30.10:FF:000002; transcription factor Sox-2; 1.
DR   Gene3D; 1.10.30.10; High mobility group box domain; 1.
DR   IDEAL; IID00626; -.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR022097; SOX_fam.
DR   InterPro; IPR050140; SRY-related_HMG-box_TF-like.
DR   PANTHER; PTHR10270; SOX TRANSCRIPTION FACTOR; 1.
DR   PANTHER; PTHR10270:SF231; TRANSCRIPTION FACTOR SOX-2; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   Pfam; PF12336; SOXp; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; HMG-box; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
DR   neXtProt; NX_P48431; -.
DR   PharmGKB; PA36032; -.
DR   TreeFam; TF351735; -.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Cytoplasm; Developmental protein; Disease variant;
KW   DNA-binding; Isopeptide bond; Methylation; Microphthalmia; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..317
FT                   /note="Transcription factor SOX-2"
FT                   /id="PRO_0000048715"
FT   DNA_BIND        41..109
FT                   /note="HMG box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          1..43
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          243..266
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          297..317
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           272..280
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000250|UniProtKB:P41225"
FT   COMPBIAS        246..261
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         42
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:29358331"
FT   MOD_RES         117
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:29358331"
FT   MOD_RES         251
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        245
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VARIANT         51
FT                   /note="W -> R (in MCOPS3; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:24033328"
FT                   /id="VAR_075627"
FT   VARIANT         74
FT                   /note="R -> P (in MCOPS3; uncertain significance;
FT                   dbSNP:rs104893805)"
FT                   /evidence="ECO:0000269|PubMed:24033328"
FT                   /id="VAR_075628"
FT   VARIANT         79
FT                   /note="W -> S (in MCOPS3; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:24033328"
FT                   /id="VAR_075629"
FT   MUTAGEN         42..43
FT                   /note="KR->AA: In mt1; reduced nuclear import; when
FT                   associated with 56-A--A-58. In mt1.2; reduced nuclear
FT                   import; when associated with 56-A--A-58 and 113-A--A-115."
FT                   /evidence="ECO:0000269|PubMed:19349578"
FT   MUTAGEN         42
FT                   /note="K->R: Loss of interaction with L3MBTL3. Loss of
FT                   ubiquitination by the CRL4-DCAF5 E3 ubiquitin ligase
FT                   complex. Loss of interaction with PHF20L1; when associated
FT                   with R-117."
FT                   /evidence="ECO:0000269|PubMed:29358331,
FT                   ECO:0000269|PubMed:30442713"
FT   MUTAGEN         56..58
FT                   /note="RRK->AAA: In mt1; reduced nuclear import; when
FT                   associated with 56-A--A-58. In mt1.2; reduced nuclear
FT                   import; when associated with 42-A-A-43 and 113-A--A-115."
FT                   /evidence="ECO:0000269|PubMed:19349578"
FT   MUTAGEN         113..115
FT                   /note="RRK->AAA: In mt2; reduced nuclear import. In mt1.2;
FT                   reduced nuclear import; when associated with 42-A-A-43 and
FT                   56-A--A-58."
FT                   /evidence="ECO:0000269|PubMed:19349578"
FT   MUTAGEN         117
FT                   /note="K->R: Loss of interaction with PHF20L1; when
FT                   associated with R-42."
FT                   /evidence="ECO:0000269|PubMed:29358331"
FT   HELIX           47..62
FT                   /evidence="ECO:0007829|PDB:6WX8"
FT   HELIX           68..79
FT                   /evidence="ECO:0007829|PDB:6WX8"
FT   HELIX           84..103
FT                   /evidence="ECO:0007829|PDB:6WX8"
FT   HELIX           108..110
FT                   /evidence="ECO:0007829|PDB:6WX8"
SQ   SEQUENCE   317 AA;  34310 MW;  EFCCAFE3E3A2B67B CRC64;
     MYNMMETELK PPGPQQTSGG GGGNSTAAAA GGNQKNSPDR VKRPMNAFMV WSRGQRRKMA
     QENPKMHNSE ISKRLGAEWK LLSETEKRPF IDEAKRLRAL HMKEHPDYKY RPRRKTKTLM
     KKDKYTLPGG LLAPGGNSMA SGVGVGAGLG AGVNQRMDSY AHMNGWSNGS YSMMQDQLGY
     PQHPGLNAHG AAQMQPMHRY DVSALQYNSM TSSQTYMNGS PTYSMSYSQQ GTPGMALGSM
     GSVVKSEASS SPPVVTSSSH SRAPCQAGDL RDMISMYLPG AEVPEPAAPS RLHMSQHYQS
     GPVPGTAING TLPLSHM
//
